Literature DB >> 17297559

Post-transcriptional modifications of VEGF-A mRNA in non-ischemic dilated cardiomyopathy.

Jacek Kowalczyk1, Dorota Domal-Kwiatkowska, Urszula Mazurek, Michał Zembala, Bogdan Michalski, Marian Zembala.   

Abstract

Vascular endothelial growth factor (VEGF-A) is one of the most important proangiogenic factors. It has many isoforms encoded by one gene. The occurrence of these isoforms is associated with the process of alternative splicing of mRNA. Some of the splice forms are perceived as tissue specific. The aim of this study was to determine the alternative splicing of VEGF-A mRNA in dilated cardiomyopathy, especially at the level of particular myocardial layers. The assessment of post-transcriptional modifications of VEGF-A mRNA was made on specimens taken from the explanted hearts of patients undergoing cardiac transplantation. Molecular and histopathological studies were perfomed on particular layers of the myocardial muscle (endocardium, myocardium, epicardium). A molecular analysis of cardiac samples was performed by quantitative analysis of the mRNA of the studied VEGF-A isoforms (VEGF121,-145,-165,-183,-189, and-206) using QRTPCR with an ABI-PRISM 7700-TaqMan sequence detector. 72 cardiac specimens taken from the explanted hearts were analyzed. Each of the studied VEGF-A splice forms was present in the evaluated hearts, but the types of alternative splicing of mRNA were different in particular layers. Quantitative analysis revealed different amounts of the studied isoforms. Generally, significantly increased expression of the VEGF-A isoforms was observed in samples taken from hearts with post-inflammatory etiology of cardiomyopathy. Our conclusions are: 1. All the studied VEGF-A isoforms were found in the human hearts, including those thusfar considered characteristic for other tissues. 2. Significant differences were observed in the expression of the VEGF-A splice forms with respect to the myocardial layers and the location of the cardiac biopsy. 3. Repetitive and comparable results for samples with post-inflammatory etiology were obtained, and they revealed considerably higher amounts of VEGF-A isoforms compared to specimens with idiopathic etiology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297559      PMCID: PMC6275580          DOI: 10.2478/s11658-007-0006-1

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  43 in total

1.  VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide.

Authors:  Jerome W Breslin; Peter J Pappas; Joaquim J Cerveira; Robert W Hobson; Walter N Durán
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09-12       Impact factor: 4.733

2.  Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance.

Authors:  A Kranz; C Rau; M Kochs; J Waltenberger
Journal:  J Mol Cell Cardiol       Date:  2000-01       Impact factor: 5.000

3.  Expression of vascular endothelial growth factor in patients with acute myocardial infarction.

Authors:  Y Hojo; U Ikeda; Y Zhu; M Okada; S Ueno; H Arakawa; H Fujikawa; T Katsuki; K Shimada
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

4.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.

Authors:  T K Rosengart; L Y Lee; S R Patel; T A Sanborn; M Parikh; G W Bergman; R Hachamovitch; M Szulc; P D Kligfield; P M Okin; R T Hahn; R B Devereux; M R Post; N R Hackett; T Foster; T M Grasso; M L Lesser; O W Isom; R G Crystal
Journal:  Circulation       Date:  1999-08-03       Impact factor: 29.690

5.  Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.

Authors:  S Rajagopalan; M Shah; A Luciano; R Crystal; E G Nabel
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

6.  [Expression patterns in isoforms of vascular endothelial growth-factors in tissue samples of vulval cancer T1 N2M0 stage].

Authors:  Bogdan Michalski; Urszula Mazurek; Anita Olejek; Tomasz Loch; Michał Graniczka; Ryszard Poreba; Tadeusz Wilczok
Journal:  Ginekol Pol       Date:  2003-01       Impact factor: 1.232

7.  Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells.

Authors:  H Gitay-Goren; T Cohen; S Tessler; S Soker; S Gengrinovitch; P Rockwell; M Klagsbrun; B Z Levi; G Neufeld
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

8.  Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

Authors:  D R Senger; S R Ledbetter; K P Claffey; A Papadopoulos-Sergiou; C A Peruzzi; M Detmar
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

9.  Rat brain VEGF expression in alveolar hypoxia: possible role in high-altitude cerebral edema.

Authors:  F Xu; J W Severinghaus
Journal:  J Appl Physiol (1985)       Date:  1998-07

10.  Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.

Authors:  V Vincenti; C Cassano; M Rocchi; G Persico
Journal:  Circulation       Date:  1996-04-15       Impact factor: 29.690

View more
  1 in total

1.  SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion.

Authors:  Christopher K Yunker; William Golembieski; Nancy Lemke; Chad R Schultz; Simona Cazacu; Chaya Brodie; Sandra A Rempel
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.